Despite promising advances in AO‐mediated exon skipping for DMD, some challenges remain for future development and to become a common strategy for treating DMD patients, such as the need for continuous weekly or biweekly administration to maintain therapeutic benefit. This evidence concerns the gene DMD and Duchenne muscular dystrophy.